On 28th November,overall volumes in futures & options currently stand at 1.72 crore contracts with a turnover of Rs. 12,08,610.01 crore.

On 28th November,overall volumes in futures & options currently stand at 1.72 crore contracts with a turnover of Rs. 12,08,610.01 crore.

The day is likely to start at a flat to negative note for the domestic markets. At the beginning of the day, there could be jitters among market participants on waning prospects of a deal between the world’s two largest economies, that is, the US and China, after the US President Donald Trump signed legislation that expresses the US support for Hong Kong protesters.

Technically, the Nifty is currently placed at a crucial juncture or a hurdle of 12,103-12,133 levels and a sustainable move above this zone could lead the index towards our short term target of 12,240-12,300. In case of any setbacks, immediate support is seen on the downside in the zone of 12,000-12,040. Stocks in news: Balaji Amines, Cipla, RBL Bank, Jet Airways, Manappuram Finance, Indian Overseas Bank.

Retirement remains the most important financial goal of an individual and the responsibility of meeting this goal is completely on them.

ARSS, even though it saw strong order inflow, failed to uplift the stock price, which tanked to its 52 Low in October 2019. The stock recently touched its 52 week low of Rs. 19 on BSE.

Looking at today’s fast-paced world, apart from maintaining your physical health, it is also important to keep yourself financially fit. Let's take a look at a few things, essential for your financial fitness.

BASF intimated the exchanges about its intent to double the production capacity for polymer dispersions with a new production line at its site, located in Dahej in India. The company aims to provide a reliable supply of high-quality dispersion solutions to customers in the current fast-growing Indian and South Asian markets through this investment.

Ashok Leyland received an order for 1,750 buses from Tamil Nadu State Transport Undertakings (TN STU) for 1,750.

Earlier this month, Biocon Biologics, had received the Establishment Inspection Report (EIR) from the USFDA, which stated that the inspection was done. A fresh start of manufacturing in the facility can be expected to give positive momentum to the company, going ahead.